Natalie Clayton is the leader of Alston & Bird’s Biotechnology, Pharmaceutical & Life Sciences Patent Litigation team. She has extensive experience litigating intellectual property matters throughout the U.S., with particularly in the pharmaceutical space.
She has been involved in patent cases covering diverse areas of technology, including pharmaceuticals, animal health, medical devices, and chemicals. Natalie has represented clients in the pharmaceutical industry in trademark, false advertising, and unfair competition cases brought under the Lanham Act.
Natalie has substantial experience in FDA regulations related to bringing these drugs to market. Natalie has represented clients in federal courts across the country and before the International Trade Commission (ITC), Federal Circuit, and Second Circuit.
Highlights include representing the petitioner before the ITC in one of the only pharmaceutical cases brought in the jurisdiction; obtaining a determination of noninfringement for a pharmaceutical client that allowed them to be first to market; obtaining a $106 million jury verdict for a pharmaceutical client in a breach of patent license case; obtaining treble damages, attorneys’ fees.
Natalie actively participates in several pro bono projects, including representing Sustainable Health Enterprises, a nonprofit organization that seeks to bring market-based solutions to developing countries.